Abstract:Highlights • In this study, we successfully developed an innovative nanodelivery system termed ICG@MnO 2 @Exo-anti-PD-L1 NPs for combining photodynamic therapy (PDT) effect with immunotherapy of non-small cell lung cancer (NSCLC). • The hollow MnO 2 nanoplatform enables a more substantial photosensitizer loading to heighten PDT, and mitigates tumor hypoxia by catalyzing the conversion of H 2 O 2 into O 2 through MnO 2 . • The generation of Mn 2+ through redox reactions due to the high level of intratumoral H 2 O 2 and H + induces polarization of M2 macrophages to M1. This, in conjunction with anti-PD-L1, activates T cells, enhancing the effectiveness of immunotherapy. Traditional treatments against advanced non-small cell lung cancer (NSCLC) with high morbidity and mortality continue to be dissatisfactory. Given this situation, there is an urgent requirement for alternative modalities that provide lower invasiveness, superior clinical effectiveness, and minimal adverse effects. The combination of photodynamic therapy (PDT) and immunotherapy gradually become a promising approach for high-grade malignant NSCLC. Nevertheless, owing to the absence of precise drug delivery techniques as well as the hypoxic and immunosuppressive characteristics of the tumor microenvironment (TME), the efficacy of this combination therapy approach is less than ideal. In this study, we construct a novel nanoplatform that indocyanine green (ICG), a photosensitizer, loads into hollow manganese dioxide (MnO 2 ) nanospheres (NPs) (ICG@MnO 2 ), and then encapsulated in PD-L1 monoclonal antibodies (anti-PD-L1) reprogrammed exosomes (named ICG@MnO 2 @Exo-anti-PD-L1), to effectively modulate the TME to oppose NSCLC by the synergy of PDT and immunotherapy modalities. The ICG@MnO 2 @Exo-anti-PD-L1 NPs are precisely delivered to the tumor sites by targeting specially PD-L1 highly expressed cancer cells to controllably release anti-PD-L1 in the acidic TME, thereby activating T cell response. Subsequently, upon endocytic uptake by cancer cells, MnO 2 catalyzes the conversion of H 2 O 2 to O 2 , thereby alleviating tumor hypoxia. Meanwhile, ICG further utilizes O 2 to produce singlet oxygen ( 1 O 2 ) to kill tumor cells under 808 nm near-infrared (NIR) irradiation. Furthermore, a high level of intratumoral H 2 O 2 reduces MnO 2 to Mn 2+ , which remodels the immune microenvironment by polarizing macrophages from M2 to M1, further driving T cells. Taken together, the current study suggests that the ICG@MnO 2 @Exo-anti-PD-L1 NPs could act as a novel drug delivery platform for achieving multimodal therapy in treating NSCLC. Graphical abstract Herein, we have constructed hollow MnO 2 NPs loaded with ICG (ICG@MnO 2 ), and then are encapsulated in DCs-derived exosomes treated with azide choline (AECho) via click chemistry reaction to obtain ICG@MnO 2 @Exo. The exosomes are reprogrammed using PD-L1 monoclonal antibodies (anti-PD-L1), generating ICG@MnO 2 @Exo-anti-PD-L1 to effectively modulate the TME and combat NSCLC through the synergistic effects of PDT and immunotherapy. In detail, an LLC (lewis lung carcinoma cells) allograft model in C57BL/6 mice was constructed and ICG@MnO 2 @Exo-anti-PD-L was injected through the tail vein. By specifically targeting cancer cells with high PD-L1 expression, the ICG@MnO 2 @Exo-anti-PD-L1 nanospheres (NPs) are precisely delivered to the tumor site and release anti-PD-L1 in the acidic TME, thereby activating T cell responses. Upon internalization by cancer cells, MnO 2 catalyzes the conversion of hydrogen peroxide (H 2 O 2 ) to oxygen, alleviating tumor hypoxia. In addition, ICG utilizes oxygen to generate singlet oxygen ( 1 O 2 ) under near-infrared (NIR) irradiation at 808 nm, leading to the destruction of tumor cells. Furthermore, the high levels of intratum oral H 2 O 2 and H + reduces MnO 2 to Mn 2+ , which remodels the immune microenvironment by polarizing macrophages from M2 to M1, thereby further stimulating T cell responses. Collectively, the findings of this study suggest that ICG@MnO 2 @Exo-anti-PD-L1 NPs can serve as a novel drug del -Abstract Truncated-

Amplifying T cell‐mediated antitumor immune responses in nonsmall cell lung cancer through photodynamic therapy and anti‐PD1

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.

Reprogramming exosomes for immunity-remodeled photodynamic therapy against non-small cell lung cancer

Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature

Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy

Investigation of the efficacy and feasibility of combined therapy of PD‐L1‐enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive‐stage small cell lung cancer

Photodynamic therapy upregulates expression of HIF-1α and PD-L1 in related pathways and its clinical relevance in non-small-cell lung cancer

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer]

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

Sensitization of Epidermal Growth Factor Receptor (EGFR) Inhibitors Induced by Radiotherapy Combined with Programmed Death Ligand-1 (PD-L1) Inhibitors

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

Pheophorbide A–Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD–L1 Expression

Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.

Enhanced systemic antitumor efficacy of PD‐1/PD‐L1 blockade with immunological response induced by photodynamic therapy

PARP Inhibitor Plus Radiotherapy Reshapes an Inflamed Tumor Microenvironment That Sensitizes Small Cell Lung Cancer to the Anti-Pd-1 Immunotherapy.

Reversing EZH2‐Mediated Epigenetic Silence with Photodynamic Polymeric Nanoparticles for Synergistically Enhanced Antitumor Immunotherapy

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model